Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

376M-9

Sigma-Aldrich

S100P (16/f5) Mouse Monoclonal Antibody

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

Quality Level

100
500

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

16/f5, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (376M-94)
vial of 0.5 mL concentrate (376M-95)
bottle of 1.0 mL predilute (376M-97)
vial of 1.0 mL concentrate (376M-96)
bottle of 7.0 mL predilute (376M-98)

manufacturer/tradename

Cell Marque™

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500

isotype

IgG1κ

control

breast, pancreatic ductal adenocarcinoma, urothelial carcinoma

shipped in

wet ice

storage temp.

2-8°C

visualization

cytoplasmic, nuclear

Gene Information

human ... S100P(6286)

Related Categories

General description

S100P is a member of the S100 family of proteins. The family is expressed in a wide range of cells and is thought to play a role in cell cycle progression and in differentiation. S100P was initially identified in the placenta at rather high levels. Anti-S100P with nuclear or nuclear/ cytoplasmic immunoreactivity can be seen in essentially 100% of pancreatic ductal adenocarcinoma in pancreatic resection, and fine needle aspiration biopsy specimens. Anti-S100P displays no staining in the benign pancreatic ducts and acinar glands. S100P has been detected in the cells of virtually all intraductal papillary mucinous neoplasms tested. S100P is clearly expressed in the invasive component of intraductal papillary mucinous neoplasms (100%), including perineural, lymphatic, and minimal invasion. Biopsies of bile ducts with primary adenocarcinomas (90%) have exhibited strong nuclear and cytoplasmic staining for anti-S100P, with none of the 32 benign biopsies exhibiting anti-S100P immunoreactivity. An immunohistochemical panel including anti-S100P can be helpful in distinguishing adenocarcinoma from reactive epithelial changes on challenging bile duct biopsies. The detection of S100P expression may help distinguish urothelial carcinomas from other genitourinary neoplasms that enter into the differential diagnosis.

Quality


IVD
IVD
IVD
RUO

Linkage

S100P Positive Control Slides, Product No. 376S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Regulatory Information

监管及禁止进口产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tatjana Crnogorac-Jurcevic et al.
The Journal of pathology, 201(1), 63-74 (2003-09-02)
In order to expand our understanding of the molecular changes underlying the complex pathology of pancreatic malignancy, global gene expression profiling of pancreatic adenocarcinoma compared with normal pancreatic tissue was performed. Human cDNA arrays comprising 9932 elements were interrogated with
Fan Lin et al.
The American journal of surgical pathology, 32(1), 78-91 (2007-12-29)
Recently, we demonstrated von Hippel-Lindau gene product (pVHL) was expressed in normal pancreatic ducts but absent in pancreatic ductal adenocarcinoma (PDA). Previous studies have suggested the diagnostic value of S100P, S100A4, and S100A6 in PDA. In this study, we evaluated
John P T Higgins et al.
The American journal of surgical pathology, 31(5), 673-680 (2007-04-27)
The morphologic distinction between prostate and urothelial carcinoma can be difficult. To identify novel diagnostic markers that may aid in the differential diagnosis of prostate versus urothelial carcinoma, we analyzed expression patterns in prostate and bladder cancer tissues using complementary
Kohei Nakata et al.
Human pathology, 41(6), 824-831 (2010-02-16)
Intraductal papillary mucinous neoplasms of the pancreas are subclassified based on morphological features, and different immunohistochemical profiles have been identified in association with the subtypes. We previously reported that S100P was an early developmental marker of pancreatic carcinogenesis and that
Hongbing Deng et al.
American journal of clinical pathology, 129(1), 81-88 (2007-12-20)
Even though the cytologic criteria for pancreatic ductal adenocarcinoma (PDA) on fine-needle aspiration biopsy (FNAB) specimens have been well defined, a diagnostic challenge is still present. We immunohistochemically evaluated the diagnostic value of S100P on cell-block and/or smear preparations in
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service